98%
921
2 minutes
20
Neurodegenerative disorders exhibit considerable clinical heterogeneity and are frequently misdiagnosed. This heterogeneity is often neglected and difficult to study. Therefore, innovative data-driven approaches utilizing substantial autopsy cohorts are needed to address this complexity and improve diagnosis, prognosis and fundamental research. We present clinical disease trajectories from 3,042 Netherlands Brain Bank donors, encompassing 84 neuropsychiatric signs and symptoms identified through natural language processing. This unique resource provides valuable new insights into neurodegenerative disorder symptomatology. To illustrate, we identified signs and symptoms that differed between frequently misdiagnosed disorders. In addition, we performed predictive modeling and identified clinical subtypes of various brain disorders, indicative of neural substructures being differently affected. Finally, integrating clinical diagnosis information revealed a substantial proportion of inaccurately diagnosed donors that masquerade as another disorder. The unique datasets allow researchers to study the clinical manifestation of signs and symptoms across neurodegenerative disorders, and identify associated molecular and cellular features.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11031398 | PMC |
http://dx.doi.org/10.1038/s41591-024-02843-9 | DOI Listing |
Neurology
October 2025
Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies - EpiCARE, Rome, Italy.
Objectives: Neuronal ceroid lipofuscinosis type 3 (CLN3) is a rare lysosomal storage disorder characterized by progressive neurodegeneration. No disease-modifying treatments are currently available. Miglustat, a substrate reduction therapy, has shown preclinical efficacy in CLN3 models (conference abstract).
View Article and Find Full Text PDFSci Signal
September 2025
Science Signaling, AAAS, Washington, DC 20005, USA. Email:
ε4 dysregulates systemic immunity, creating vulnerability for neurodegenerative disease.
View Article and Find Full Text PDFPLoS One
September 2025
Department of Neurology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Background: Stroke is a leading cause of death and disability globally, with frequent cognitive sequelae affecting up to 60% of stroke survivors. Despite the high prevalence of post-stroke cognitive impairment (PSCI), early detection remains underemphasized in clinical practice, with limited focus on broader neuropsychological and affective symptoms. Stroke elevates dementia risk and may act as a trigger for progressive neurodegenerative diseases.
View Article and Find Full Text PDFJ Alzheimers Dis
September 2025
Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
As plasma biomarkers like p-tau217 move towards clinical use in Alzheimer's disease (AD), it is important to understand how kidney function may influence their accuracy. Even mild chronic kidney disease (CKD) can alter biomarker levels, potentially impacting test performance. While accounting for renal function may improve specificity, it could reduce sensitivity without greatly changing overall diagnostic accuracy.
View Article and Find Full Text PDFSci Prog
September 2025
Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.
BackgroundGlaucoma is recognized as the second-leading cause of complete blindness in developed countries and a significant contributor to irreversible vision loss worldwide. Understanding the potential genetic links between neurodegenerative diseases, such as Parkinson's disease, and glaucoma is crucial for developing preventive strategies.MethodsThis study utilized data from Genome-Wide Association Studies databases, focusing on European populations without gender restrictions.
View Article and Find Full Text PDF